Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter